Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Jazz Pharmaceuticals plc - Ordinary Shares
(NQ:
JAZZ
)
109.45
-0.47 (-0.43%)
Streaming Delayed Price
Updated: 10:53 AM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jazz Pharmaceuticals plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
February 26, 2025
Via
Benzinga
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
February 26, 2025
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.
Via
StockStory
Viatris Earnings: What To Look For From VTRS
February 26, 2025
Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect.
Via
StockStory
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales
February 25, 2025
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% year on year to $1.09 billion. On the other hand, the company’s full-year...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Earnings Scheduled For February 25, 2025
February 25, 2025
Via
Benzinga
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
February 13, 2025
Via
Benzinga
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
November 04, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ): good value for what you're paying.
Via
Chartmill
In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals
October 23, 2024
Via
Benzinga
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
February 24, 2025
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look for.
Via
StockStory
NASDAQ:JAZZ is probably undervalued for the fundamentals it is displaying.
February 19, 2025
JAZZ PHARMACEUTICALS PLC may be an undervalued stock option. NASDAQ:JAZZ retains a strong financial foundation and an attractive price tag.
Via
Chartmill
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
February 13, 2025
Via
Benzinga
Investors should take notice of NASDAQ:JAZZ—it offers a great deal for the fundamentals it presents.
January 29, 2025
When you look at JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
January 08, 2025
Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
October 04, 2024
Via
Benzinga
Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued.
September 19, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.
Via
Chartmill
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
September 09, 2024
Via
Benzinga
NASDAQ:JAZZ is an undervalued gem with solid fundamentals.
December 17, 2024
Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
December 09, 2024
The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and...
Via
Benzinga
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
November 27, 2024
Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.
Via
Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
November 25, 2024
For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals.
Via
Chartmill
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
November 21, 2024
Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.
Via
Benzinga
UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy
November 08, 2024
Via
Benzinga
Topics
Cannabis
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
November 06, 2024
CEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.
Via
Benzinga
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
October 18, 2024
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!
Via
The Motley Fool
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
October 15, 2024
Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a...
Via
Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
October 14, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.
Via
Chartmill
FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
September 19, 2024
Veterans: Epidiolex shows promise in treating Gulf War Illness, offering hope for those affected. Learn how it might benefit them.
Via
Benzinga
When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
August 29, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.
Via
Chartmill
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
August 28, 2024
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and...
Via
Benzinga
'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
August 27, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.